Increasing evidence suggests that Toll-like receptor 4 (TLR4) contributes importantly to spinal cord glial activation and chronic pain sensitization; however, its unique role in acute and chronic itch is unclear. In this study, we investigated the involvement of TLR4 in acute and chronic itch models in male mice using both transgenic and pharmacological approaches. Tlr4 mice exhibited normal acute itch induced by compound 48/80 and chloroquine, but these mice showed substantial reductions in scratching in chronic itch models of dry skin, induced by acetone and diethylether followed by water (AEW), contact dermatitis, and allergic contact dermatitis on the neck. Intrathecal (spinal) inhibition of TLR4 with lipopolysaccharide Rhodobacter sphaeroides did not affect acute itch but suppressed AEW-induced chronic itch. Compound 48/80 and AEW also produced robust alloknesis, a touch-elicited itch in wild-type mice, which was suppressed by intrathecal lipopolysaccharide R sphaeroides and Tlr4 deletion. Acetone and diethylether followed by water induced persistent upregulation of Tlr4 mRNA and increased TLR4 expression in GFAP-expressing astrocytes in spinal cord dorsal horn. Acetone and diethylether followed by water also induced TLR4-dependent astrogliosis (GFAP upregulation) in spinal cord. Intrathecal injection of astroglial inhibitor L-α-aminoadipate reduced AEW-induced chronic itch and alloknesis without affecting acute itch. Spinal TLR4 was also necessary for AEW-induced chronic itch in the cheek model. Interestingly, scratching plays an essential role in spinal astrogliosis because AEW-induced astrogliosis was abrogated by putting Elizabethan collars on the neck to prevent scratching the itchy skin. Our findings suggest that spinal TLR4 signaling is important for spinal astrocyte activation and astrogliosis that may underlie alloknesis and chronic itch.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946956 | PMC |
http://dx.doi.org/10.1097/j.pain.0000000000000439 | DOI Listing |
Int Immunopharmacol
January 2025
Institute of Molecular Immunology, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong 510515, China. Electronic address:
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder characterized by intense pruritus and complex immunopathogenic mechanisms. Recent evidence has highlighted the critical link between dysregulated intestinal microecology and altered immune responses in AD progression. As essential components of the intestinal microenvironment, metabolites play pivotal roles in various physiological processes.
View Article and Find Full Text PDFArch Dermatol Res
January 2025
Department of Dermatology, Stanford University School of Medicine, 450 Broadway Street Pavilion B, 4th Floor, Redwood City, CA, 94063, USA.
Allergy
January 2025
St John's Institute of Dermatology, Guy's Hospital, London, UK.
Background: This study compared the therapeutic equivalence of CT-P39 (an omalizumab biosimilar) and EU-approved reference omalizumab (ref-OMA) in patients with chronic spontaneous urticaria.
Methods: This double-blind, randomized, active-controlled Phase 3 study (NCT04426890) included two 12-week treatment periods (TPs). In TP1, patients received CT-P39 300 mg, ref-OMA 300 mg, CT-P39 150 mg, or ref-OMA 150 mg.
Vet Dermatol
January 2025
Department of Veterinary Medicine, School of Medicine and Life Sciences, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil.
Background: Chronic and recurrent pyoderma in dogs is driving a growing interest in natural antimicrobial products that offer minimal adverse effects and avoid antibiotic resistance.
Objectives: Evaluate the safety and efficacy of dermatological products with antimicrobial peptides and plant extracts, comparing them to chlorhexidine + miconazole and cephalexin therapy for superficial pyoderma in dogs.
Materials And Methods: Forty-five dogs with superficial pyoderma underwent clinical, cytopathological and microbiological diagnosis, and were randomly assigned to Group 1 (G1) treated with shampoo (two weekly baths) and lotion (twice daily on the affected areas) containing natural antimicrobials; Group 2 (G2) treated with two weekly baths using a therapeutic shampoo containing 2% chlorhexidine and 2.
Hepatol Commun
December 2024
Division of Gastroenterology and Hepatology, Department of Medicine, The Autoimmune and Rare Liver Disease Programme, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!